Hawkary Pharmaceuitcal CO.

Hawkary Pharmaceutical Co. is a leading pharmaceutical distribution company based in Erbil, Iraq. Established in 1992, it has rapidly ascended to become one of the top five fastest-growing local pharmaceutical distributors in the country, securing a significant market share. The company specializes in the distribution and marketing of pharmaceutical products, continually expanding its portfolio to meet the evolving needs of the Iraqi pharmaceutical market.

Under the leadership of Dr. Muhammed Ismail Seyan, who serves as the Chairman and Acting CEO, Hawkary has implemented advanced systems such as Enterprise Resource Planning (ERP) to enhance operational efficiency. This integration facilitates seamless information flow across business functions and regional offices, ensuring timely delivery of quality products.

Hawkary's distribution network spans the entire Iraqi territory, encompassing major cities such as Erbil, Baghdad, Basra, Karbala, Tikrit, Sulaymaniyah, Duhok, Mosul, and Kirkuk. The company operates a substantial warehouse with a capacity of 25,000 pallets, adhering to European and U.S. FDA guidelines for Good Distribution Practice (GDP). This commitment ensures the maintenance of high-quality standards in the storage and distribution of medical products.

In Iraq's pharmaceutical supply chain, Hawkary Pharmaceutical Co. functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, the company plays a pivotal role in ensuring the availability of a diverse range of medications across the nation. Its extensive distribution network and adherence to international standards underscore its significant position in the market.

Hawkary's sourcing strategy exhibits a high degree of concentration, with a total import value of $3.4 million USD from India over 79 shipments, all sourced from a single supplier, AJANTA PHARMA LIMITED. This exclusive partnership indicates a strategic choice to maintain a consistent supply chain and potentially negotiate favorable terms. However, such dependency also poses risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the sole supplier. The absence of alternative suppliers may limit Hawkary's ability to diversify its product offerings and mitigate potential supply chain vulnerabilities.

The resilience of Hawkary's Indian supply chain is contingent upon the stability and reliability of AJANTA PHARMA LIMITED. The lack of backup suppliers and limited formulation diversity within the current sourcing strategy heightens the company's exposure to potential disruptions. Factors such as geopolitical tensions, regulatory changes, or operational challenges within the supplier's facilities could adversely impact Hawkary's ability to meet market demand. Additionally, the reliance on a single supplier may affect the company's capacity to adapt to evolving market needs and introduce new products.

Hawkary's concentrated sourcing pattern positions the company to leverage strong relationships with its sole supplier, potentially securing favorable pricing and consistent product quality. However, this strategy also exposes Hawkary to significant risks associated with supply chain disruptions and regulatory changes affecting the supplier. For Indian exporters seeking to become alternative suppliers, this presents an opportunity to diversify Hawkary's sourcing base, thereby enhancing supply chain resilience and reducing dependency on a single source. Engaging with Hawkary could lead to a mutually beneficial partnership, offering Indian exporters access to the Iraqi market while providing Hawkary with a more diversified and robust supply chain.

In Iraq, the Ministry of Health (MOH) through the Iraq Drug Regulatory Authority (IDRA) oversees the regulation of pharmaceutical imports. The IDRA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Iraqi market. This includes the approval of marketing authorizations, pricing oversight, pharmacovigilance, inspections, import permissions, and promotion rules. Quality and standards are further regulated by the Central Organization for Standardization and Quality Control (COSQC), which operates under the Ministry of Planning.

Pharmaceutical products imported into Iraq must be registered with the IDRA, which requires evidence of Good Manufacturing Practice (GMP) compliance. The registration process involves submitting documentation that demonstrates the safety, efficacy, and quality of the products. Marketing authorizations are typically time-limited, commonly for five years, and are renewable with updated data. Generics follow an abbreviated, bioequivalence-driven route, while biologics and biosimilars require comparability packages. Promotion of pharmaceutical products is tightly controlled, with strict rules on interactions with healthcare professionals.

Imported pharmaceutical products must comply with Iraq's National Drug System, which mandates comprehensive registration and tracking of all pharmaceutical products and manufacturers within a centralized digital platform. Each product is required to display an electronic label featuring essential drug information, official pricing, and a unique QR code for instant verification. This labeling system provides immediate access to critical product data, including drug names, expiry dates, manufacturer details, active ingredients, side effects, warnings, and precautions.

In January 2023, the Iraqi government issued a decision to reduce the import of 23 types of medicines that are produced locally and fulfill the need. This policy aims to encourage domestic production and reduce reliance on imports for certain pharmaceutical products. The decision underscores the government's commitment to enhancing local pharmaceutical manufacturing capabilities and ensuring the availability of essential medicines within the country. (ina.iq)

Hawkary Pharmaceutical Co. focuses on importing a diverse range of pharmaceutical products, with a notable emphasis on advanced antibiotics, antibiotics, and analgesics & antipyretics. This strategic focus aligns with the therapeutic needs of the Iraqi population, addressing prevalent health concerns and conditions. The company's product portfolio is designed to meet the growing demand for effective treatments in these categories, ensuring accessibility to essential medications.

Hawkary's sourcing strategy is centered on importing finished pharmaceutical formulations from a single supplier, AJANTA PHARMA LIMITED in India. This approach allows for streamlined operations and potentially favorable terms. However, the lack of diversification in sourcing may limit the company's ability to adapt to changing market demands and introduce new products. Exploring additional suppliers could enhance the diversity and resilience of Hawkary's product offerings.

Based on its product mix, Hawkary Pharmaceutical Co. serves a broad segment of the Iraqi market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive distribution network and comprehensive product portfolio enable it to meet the diverse needs of healthcare providers and patients across the country.

There is a realistic opportunity for new Indian suppliers to engage with Hawkary Pharmaceutical Co. by offering a diversified range of pharmaceutical products. By introducing alternative sources and formulations, Indian exporters can help mitigate Hawkary's current sourcing concentration, thereby enhancing supply chain resilience and reducing dependency on a single supplier. This collaboration could lead to a mutually beneficial partnership, expanding market reach and product offerings.

Indian exporters seeking to supply Hawkary Pharmaceutical Co. must ensure that their products are registered with the Iraq Drug Regulatory Authority (IDRA) and comply with Good Manufacturing Practice (GMP) standards. Products must be accompanied by electronic labeling featuring essential drug information and a unique QR code for verification. Additionally, exporters should be prepared to navigate Iraq's regulatory framework, including import licensing requirements and quality control standards.

To establish a relationship with Hawkary Pharmaceutical Co., Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with Iraq's regulatory requirements. Participating in tenders and engaging in direct negotiations can facilitate partnership opportunities. Understanding the regulatory filing process and adhering to the necessary timelines are crucial for successful market entry. Building a strong relationship with Hawkary can lead to increased market presence and access to a significant distribution network within Iraq.